Does Tremfya (guselkumab) carry a risk of rash?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Tremfya Carry a Risk of Rash?

Yes, Tremfya (guselkumab) does carry a risk of rash, which has been specifically identified as a postmarketing adverse reaction by the FDA. 1

FDA-Documented Rash Risk

The FDA drug label explicitly lists rash as a postmarketing adverse reaction under "Skin and subcutaneous tissue disorders." 1 This means rash has been reported during post-approval use of Tremfya, though the exact frequency cannot be reliably estimated due to voluntary reporting from an uncertain population size.

Clinical Context and Injection Site Reactions

Beyond generalized rash, injection site reactions are more commonly documented and include:

  • Injection site rash (specifically listed)
  • Injection site erythema
  • Injection site pruritus
  • Injection site pain and other local reactions

In the ulcerative colitis maintenance study (UC2), injection site reactions occurred in 8.9% of patients receiving the 200 mg dose (administered as two 100 mg injections) compared to only 1% in the placebo group. 1 The higher dose formulation requiring two injections showed notably increased injection site reactions.

Overall Safety Profile

Despite the documented rash risk, guselkumab maintains a favorable overall safety profile across extensive clinical experience:

  • Over 8,662 patient-years of exposure in psoriasis studies showed consistent safety through 5 years 2
  • Integrated analysis of 10,787 patient-years across psoriasis and psoriatic arthritis studies demonstrated comparable adverse event rates to placebo 3
  • Most common adverse events were respiratory infections (nasopharyngitis, upper respiratory tract infections), not dermatologic reactions 4, 5

Clinical Implications

When counseling patients about Tremfya:

  • Inform them that rash is a recognized adverse reaction, though uncommon
  • Expect injection site reactions in approximately 9% of patients, particularly with higher doses
  • Monitor for hypersensitivity reactions, as rash may be part of a broader allergic response 1
  • Reassure patients that serious adverse events remain rare (5.3-5.4 per 100 patient-years) 2, 3

The rash risk should not deter appropriate use of guselkumab in patients with moderate-to-severe psoriasis, psoriatic arthritis, or ulcerative colitis, given its strong efficacy profile and generally favorable safety data.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.